The interference of circulating factors of the immune systemwas evaluated by spiking these proteins at physiologically relevant concentrations into a human CTLA-4 positive serum. There was no crossreactivity detected.
Standard Curve Range
0.16 - 10.0 ng/mL
ELISA Kit (Colorimetric)
The human sCTLA-4 ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human sCTLA-4
Read 1 Review rated 5 using NBP1-91268 in the following application:
ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
Cytotoxic T lymphocyte associated gene -4 (CTLA-4) was initially described as a classical type I glycoprotein on the surface of activated T-cells. CTLA-4 is a member of the Ig gene superfamily and along with its homologue, CD28, is a B7 binding protein. There is evidence that CTLA-4 is a negative regulator of T-cell activation, ligation of CTLA-4 on the T-cell surface initiates a series of biochemical events that attenuate an ongoing immune response. CTLA-4 knock out mice demonstrate profound polyclonal lymphoproliferative disoders that infiltrate most major organ systems and the animals die a few weeks after birth. The animals have increased levels of IgG which illustrates the role of CTLA-4 on humoral immune responses as well. A role for CTLA-4 in autoimmune disease is suggested by the observations that blockade of B7/CTLA-4 interaction exacerbates animal models of autoimmune disease such as experimental autoimmune encephalomyelitis and diabetes.A search for genetic markers that segregate with Graves? disease revealed an association with CTLA-4 polymorphisms. CTLA-4 is further more closely linked to autoimmune thyroid disease (ATD). A native soluble form of CTLA-4 has been described to be present in human serum. A correlation of circulating CTLA-4 and ATD has been shown.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. ELISA Kits are guaranteed for 6 months from date of receipt.
The exact protocol provided by Novus for this antibody kit was followed. No blocking details.
We did not have to dilute our samples for ELISA. We only normalized the total protein to 20 ug.
The plate was read at 450 nm using the Biotek Synergy 4 plate reader.
ELISA Plate Details
The kit contained a plate pre-coated with sCTLA-4 antibody
400 uL of the provided wash buffer was used to wash wells. We would let it sit for 10 s before aspiration. Washed 4-5X.
Make sure to read the protocol at least once all the way through before starting the ELISA. It only takes about 4-5 hours total time. Also, our standard curve did not correlate well with the standard curve provided in the protocol book (Yes, a 40 page book that is very detailed), so don't be surprised if you standard curve is off too. Our standard curve provided an r squared value > 0.98, so everything turned out great. Really liked the kit and will use it again in the future.
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
FAQs for CTLA-4 ELISA Kit (NBP1-91268). (Showing 1 - 1 of 1 FAQs).
Does this kit work with CTLA4Ig fusion protein? CTLA4Ig contains the extracellular domain of human CTLA4 and human IgG1 Fc. Do you know if any customers use this kit to check CTLA4Ig? sCTLA4 and CTLA4Ig have the same extracellular domain. If the two antibodies used in the ELISA kit are against the extracellular domain, it could be used to detect CTLA4Ig. Could you please tell me the epitopes of the two antibodies?
The standard protein in our human CTLA-4 is a soluble fusion protein consisting of the extracellular domain of human CTLA-4, fused to mouse IgG2a Fc. This means that our kit will detect your CTLA4Ig.
CD86 - I work in tandem with CD80 CD86 belongs to the immunoglobulin superfamily of proteins that drive innate and adaptive immune responses. It is an 80kD co-stimulatory molecule for the priming and activation of naive and memory T-cells, respectively. CD86 is expressed on activated... Read full blog post.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.